Revolution Medicines
RVMD
323 hedge funds and large institutions have $8.96B invested in Revolution Medicines in 2025 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 118 increasing their positions, 92 reducing their positions, and 45 closing their positions.
174% more call options, than puts
Call options by funds: $128M | Put options by funds: $47M
42% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 45
33% more funds holding in top 10
Funds holding in top 10: 18 → 24 (+6)
28% more repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 92
28% more capital invested
Capital invested by funds: $7.02B → $8.96B (+$1.94B)
5% more funds holding
Funds holding: 308 → 323 (+15)
0.24% more ownership
Funds ownership: 102.4% → 102.63% (+0.24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
+$96.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.1M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$38.9M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$33.9M |
| 5 |
Janus Henderson Group
London,
|
+$30M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$55.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$39.4M |
| 3 |
Millennium Management
New York
|
-$37.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32.4M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$28.9M |
RVMD Hedge Fund Activity: Q3 2025 in Review
323 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q3 2025, worth a combined $8.96B — up 28% from $7.02B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new RVMD positions and 45 closed out — a net gain of 19 holders — while 118 added to existing stakes and 92 trimmed.
The largest buyer was General Atlantic, opening a new position worth an estimated $96.9M. The largest seller was Goldman Sachs, cutting an estimated $55.4M.
- 323 institutional investors held Revolution Medicines (RVMD) as of Q3 2025, up from 308 in Q2 2025.
- Funds reported $8.96B of Revolution Medicines stock for Q3 2025, up 28% quarter-over-quarter.
- 64 funds opened new Revolution Medicines positions in Q3 2025 and 45 closed out, a net change of +19 holders.
- The largest Revolution Medicines buyer in Q3 2025 was General Atlantic, an estimated $96.9M added.
- The largest Revolution Medicines seller in Q3 2025 was Goldman Sachs, an estimated $55.4M sold.
Based on aggregated 13F filings for Q3 2025.